The Effect of Mankai on Glycemic Control Among Patients With T2D

Launched by BEN-GURION UNIVERSITY OF THE NEGEV · May 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a plant called Mankai on blood sugar control in people with type 2 diabetes (T2D). Researchers want to see if drinking a daily Mankai beverage can help lower a specific blood test result called HbA1c, which measures average blood sugar levels over time. The trial involves 104 participants who will either drink the Mankai beverage or plain water three times a day for three months. Throughout the study, researchers will monitor things like appetite, food intake, and any symptoms participants may experience.

To participate in this trial, individuals must be over 30 years old and have been diagnosed with T2D, either through specific blood tests or by taking diabetes medications. Participants should also have stable medication for at least three months before joining. However, those with well-controlled diabetes (HbA1c below 7%) or certain health conditions, like severe liver or kidney issues, cannot take part. This study is important because its findings could reveal a new way to help people with T2D manage their blood sugar levels through nutrition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 30 years
• • A formal diagnosis of T2D (126mg/dl fasting glucose or higher, or HbA1c\>6.5%) or taking T2D medications with HbA1c levels over 7%
• • Medication stability for at least 3 months prior to Intervention initiation
• • Adherence to medical follow-up in primary care clinic or diabetes-centered outpatient services
• Exclusion Criteria:
• • HbA1c lower than 7% or higher than 10%
• • Known insulinopenia
• • Treatment with coumadin (warfarin)
• • Advanced renal failure
• • Significantly disturbed liver enzymes (liver transaminases or bilirubin levels more than time three upper-normal-limit)
• • A significant illness that might require hospitalization
• • Regular Mankai consumption
• • State of pregnancy or lactation
• • Presence of active cancer or chemotherapy treatment in last three years
• • Participation in another trial